Gilead Sciences GILD
US equityMarket cap rank #82Drug Manufacturers - GeneralCAR-T TherapyInfectious DiseaseCancer Research
$166.89 −$0.68 (-0.41%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $166.89 0.00%
Open$164.11
Prev close$167.57
Day range$164.00 – $169.06
Volume5.82M
Market cap$207.00B
P/E (TTM)–
Dividend yield1.95%
GILD Stock News
Headlines matching Gilead Sciences or the GILD ticker, most recent first.
- Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $160
- UBS Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $175
- Maxim Group Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165
- J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $160
- A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $160 to $174
- A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $150 to $177
- Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $170
- Truist Financial Maintains Gilead Sciences(GILD.US) With Buy Rating
- BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $174
- Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177
- Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165
- Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $145
- J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $160
- Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Cuts Target Price to $166 Negative
- Cantor Fitzgerald Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $155
No comments yet — be the first to weigh in on GILD.
Sign in to join the discussion.